FDA Clears Pasithea IND for PAS-004 in Skin Tumor Condition

Pasithea Therapeutics Corp. announced that the U.S. Food and Drug Administration cleared its Investigational New Drug application for PAS-004 in a skin tumor condition, according to StreetInsider.

The reported regulatory action concerns PAS-004, which StreetInsider described as an oral macrocyclic MEK candidate. StreetInsider identified Pasithea Therapeutics Corp. as Nasdaq: KTTA.

Reported FDA action

StreetInsider reported that the FDA cleared Pasithea’s Investigational New Drug application for PAS-004. The supplied report identifies a skin tumor condition as the setting for the cleared application.

The announcement centers on the regulatory status of the named candidate rather than additional details about the program. In the supplied report, PAS-004 is described as oral, macrocyclic, and MEK-focused.

What the update identifies

• Company: Pasithea Therapeutics Corp.
• Regulatory agency: U.S. Food and Drug Administration
• Regulatory action: Investigational New Drug application clearance
• Candidate: PAS-004
• Reported setting: a skin tumor condition

StreetInsider’s report provides a focused account of the FDA clearance. It does not provide further clinical-program details in the supplied evidence.

Context for medical sales professionals

For pharmaceutical and biotechnology sales professionals, the development is a regulatory update involving Pasithea and PAS-004. Conversations about the announcement can remain anchored to the reported FDA IND clearance, the named candidate, and the stated skin tumor condition.

StreetInsider characterized PAS-004 as an oral macrocyclic MEK candidate. The available evidence does not add further details about the investigational program, so communications should distinguish the reported clearance from information not included in the report.

This brief is based on reporting from StreetInsider regarding Pasithea Therapeutics Corp.’s announcement.